474711-91-6

Upstream product

• 103-71-9 phenyl isocyanate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 295341-38-7 tert-butyl 4-(phenylcarbamoyl)piperazine-1-carboxylate 

Downstream Products

• 115994-87-1 piperazine-1-carboxylic acid phenyl amide 
• 65766-74-7 4-benzyl-piperazine-1-carboxylic acid anilide 
• 890578-27-5 C₁₈H₂₀ClN₃O 
• 896573-81-2 C₁₈H₂₀FN₃O 
• 896573-78-7 C₁₈H₂₀FN₃O 
• 1394894-38-2 C₁₉H₂₀N₄O 
• 1325964-79-1 C₁₉H₂₀N₄O 
• 439854-53-2 C₁₉H₂₀F₃N₃O 
• 925638-82-0 C₁₉H₂₀F₃N₃O 
• 1394894-39-3 C₂₄H₂₄ClN₃O₂ 
• 474696-09-8 N-phenyl-4-[6-(3-methyl-1-trityl-1H-4-pyrazolyl)-4-quinolinyl]-1-piperazinecarboxamide 

Relevant academic research and scientific papers

INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE

Disclosed are piperazine derivative compounds, particularly piperazine derivative compounds having a structure of Formula (I) and methods for preparing these compounds. Also disclosed are use of a therapeutically effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition therefore for inhibiting quorum sensing of a bacteria.

Aryl piperazinyl ureas as inhibitors of fatty acid amide hydrolase (FAAH) in rat, dog, and primate

A series of aryl piperazinyl ureas that act as covalent inhibitors of fatty acid amide hydrolase (FAAH) is described. A potent and selective (does not inhibit FAAH-2) member of this class, JNJ-40355003, was found to elevate the plasma levels of three fatt

AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS

The present invention relates to compounds of formula I, which exhibit affinity for the farnesoid X receptor.

PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE

Compounds of formula (I) : wherein, Z is -N-or>CH; R1 is -H or -C1-4alkyl; Ar1 is 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-primidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring member with one or two Ra moieties; Wher each Ra moiety is independently selected from the group consisting of -C1-4alkyl, -C2-4alkenyl, -OH, -OC1-4alkyl, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkyl, -OSO2C1-4alkyl, -CO2C1-4alkyl, -CO2H, -COC1-4alkyl, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, and -CN, wherein Rb and Rc are each independently -H or -C1-4alkyl; and Ar2 is defined in the claims are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.

Novel 1-piperazinecarboxamide derivatives

A series of 1-piperazinecarboxamide derivatives of the following formula: STR1 The compounds of the present invention are neuropharmacological agents intended for the treatment of mental disorders, such as psychoses and depression.

Piperazinecarboxamides having a phenoxyalkyl or thiophenoxyalkyl side chain

Novel compounds of formula (I), wherein R1 is selected from hydrogen, halogen; or trifluoromethyl; X is oxygen or sulfur; R2 and R3 are the same or different and selected from hydrogen or lower alkyl; m is 2 or 3; Y is oxygen or sulphur; Z is selected from: --NR4 R5, formulae (II), (III) or (IV), wherein R4 and R5 are the same or different and selected from hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy-alkyl, alkoxyalkyl or alkanoyloxyalkyl, phenyl or phenyl-alkyl, wherein the phenyl groups may be unsubstituted or monosubstituted with halogen or CF3 ; n is 0, 1, 2 or 3; R6 and R7 are the same or different and selected from hydrogen, lower alkyl, hydroxy, lower alkoxy or lower alkanoyloxy; p is 2 or 3; R8 and R9 are the same or different and selected from hydrogen or lower alkyl; R10 is hydrogen, lower alkyl or lower alkanoyl. The new compounds can be used for treating mental disorders.